Background To assess the worldwide variation of amyotrophic lateral sclerosis (ALS)
incidence, we performed a systematic review and meta-analysis of population-based data …

Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …

Although amyotrophic lateral sclerosis (ALS) is relatively rare, the socioeconomic
significance of the disease is extensive. It is therefore vital to project the epidemiologic trend …

Background Amyotrophic lateral sclerosis shares characteristics with some cancers, such as
onset being more common in later life, progression usually being rapid, the disease affecting …

Background Amyotrophic lateral sclerosis (ALS) is a progressive debilitating
neurodegenerative disease, with a life expectancy of 3–5 years from first symptom. There is …

Most health-care professionals are trained to promote and maintain life and often have
difficulty when faced with the often rapid decline and death of people with terminal illnesses …

Amyotrophic lateral sclerosis (ALS) epidemiology has rapidly developed in the last 30 years
alongside the evolving changes in concepts in the field of clinical ALS and also due to the …

Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS)
although it is reported by most of these patients. It occurs at all stages of the disease and can …

Introduction ALS functional rating scale (revised)(ALSFRS-R) is the most widely used
functional rating system in patients with amyotrophic lateral sclerosis (ALS). However …

Prospective population based-registers of amyotrophic lateral sclerosis (ALS) have operated
in Europe for over two decades, and have provided important insights into our …